US 11274303
Olmalinc as a diagnostic and therapeutic target for NAFLD, NASH, metabolic syndrome, and hepatic fibrosis
granted A61KA61K31/713A61K45/06
Quick answer
US patent 11274303 (Olmalinc as a diagnostic and therapeutic target for NAFLD, NASH, metabolic syndrome, and hepatic fibrosis) held by The United States Government represented by the Department of Veterans Affairs expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States Government represented by the Department of Veterans Affairs
- Grant date
- Tue Mar 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 10
- CPC classes
- A61K, A61K31/713, A61K45/06